Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients

Lugli, Alessandro

doi:10.3748/wjg.v16.i38.4823

Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients

Date Issued

2010-01-01

Author(s)

Zlobec, Inti

Molinari, Francesca

Martin, Vittoria

Mazzucchelli, Luca

Saletti, Piercarlo

Trezzi, Rosangela

De Dosso, Sara

Vlajnic, Tatjana

Frattini, Milo

Lugli, Alessandro

DOI

10.3748/wjg.v16.i38.4823

Abstract

To investigate whether the evaluation of tumor budding can complement K-RAS analysis to improve the individualized prediction of response to anti-epidermal growth factor receptor based therapies in metastatic colorectal cancer (mCRC) patients.